Toboroz
Tier Palliative Care For Patients With Advanced Heart Failure or Cancer
NCT07391956· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Laura Gelfman, MD, MPH
Toboroz
Vestibular Innovation in Pain 2
NCT07423377· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Michael Kaplan (principal investigator)
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Stephanie V. Blank (principal investigator)
Toboroz
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Robert M. Samstein (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Dmitriy Zamarin (principal investigator)
Toboroz
Evaluating a Prototype CT Scan for ICH Evacuation
NCT07455201· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Christopher Kellner (principal investigator)
Toboroz
Validating CGM for GDM
NCT06858787· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Shelly Thai, MD
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: Karyn A. Goodman (principal investigator)
Még nem toboroz
ExosomeDx in MRI-negative Men With High PSA
NCT06966089· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Craig Nobert (sub-investigator)
Toboroz
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· 3. fázis· Joseph Broderick, MD· Forrás
Contact: John W Liang, MD
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
NCT06999122· EMVision Medical Devices Ltd· Forrás
Contact: Megha Dhillon
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Stephanie V. Blank (principal investigator)
Toboroz
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371· 2. fázis· Cytokinetics· Forrás
Contact: Cytokinetics MD
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418· Cleerly, Inc.· Forrás
Contact: Waqas A Malick, MD
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Daniel R. Dickstein (principal investigator)
Fut, nem toboroz
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
NCT05836584· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487· Endotronix, Inc.· Forrás
Contact: Sajiny John
Toboroz
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Karyn A. Goodman (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Melanie W. Kier (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Peter S. Kozuch (principal investigator)
Fut, nem toboroz
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883· 3. fázis· Joseph Broderick, MD· Forrás
Toboroz
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT05095207· 1/2. fázis· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Laura A Fiedler, MPH
Toboroz
Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder
NCT05160129· Icahn School of Medicine at Mount Sinai· Forrás
Contact: Martijn Figee
Meghívásos bevonás
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT05368038· Albert Einstein College of Medicine· Forrás
Fut, nem toboroz
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Bobby Liaw (principal investigator)
Toboroz
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Forrás
Contact: Stephanie V. Blank (principal investigator)
Fut, nem toboroz
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· 3. fázis· Yale University· Forrás
Contact: Neha Dangayach, MD
Fut, nem toboroz
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985· W.L.Gore & Associates· Forrás
Fut, nem toboroz
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
NCT03567707· Korai 1. fázis· National Institute of Allergy and Infectious Diseases (NIAID)· Forrás
Toboroz
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Forrás
Contact: Amy D. Tiersten (principal investigator)
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
NCT03304080· 1/2. fázis· Icahn School of Medicine at Mount Sinai· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 56.